Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
GW Pharmaceuticals plc stock logo
GWPH
GW Pharmaceuticals
$218.96
$218.59
$87.07
$219.57
$6.86B2.15899,771 shsN/A
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
$18.25
+7.7%
$16.23
$10.68
$20.73
$3.18B0.81123,286 shs121,676 shs
Legend Biotech Co. stock logo
LEGN
Legend Biotech
$47.45
+0.8%
$58.82
$45.52
$77.32
$8.63B0.011.00 million shs1.81 million shs
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$117.12
+0.1%
$126.18
$55.25
$159.89
$11.00B0.94977,215 shs440,864 shs
Mawson Infrastructure Group Inc. stock logo
WIZP
Mawson Infrastructure Group
$1.51
-3.8%
$1.47
$0.07
$1.45
$734.35M1.77141,517 shs877,017 shs
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
GW Pharmaceuticals plc stock logo
GWPH
GW Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
+7.73%+9.41%+11.35%+34.69%+11.69%
Legend Biotech Co. stock logo
LEGN
Legend Biotech
+0.83%-5.33%-18.39%-21.05%-30.28%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
+0.14%-0.14%-8.17%-2.58%-7.55%
Mawson Infrastructure Group Inc. stock logo
WIZP
Mawson Infrastructure Group
+31.93%+62.53%+9.03%-25.59%-50.32%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
GW Pharmaceuticals plc stock logo
GWPH
GW Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
1.5391 of 5 stars
3.42.00.00.03.20.00.6
Legend Biotech Co. stock logo
LEGN
Legend Biotech
2.4491 of 5 stars
4.51.00.00.01.91.70.6
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
4.8816 of 5 stars
4.44.00.04.22.02.51.9
Mawson Infrastructure Group Inc. stock logo
WIZP
Mawson Infrastructure Group
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
GW Pharmaceuticals plc stock logo
GWPH
GW Pharmaceuticals
N/AN/AN/AN/A
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
2.75
Moderate Buy$29.7062.74% Upside
Legend Biotech Co. stock logo
LEGN
Legend Biotech
2.92
Moderate Buy$83.2675.46% Upside
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
2.80
Moderate Buy$158.3835.22% Upside
Mawson Infrastructure Group Inc. stock logo
WIZP
Mawson Infrastructure Group
N/AN/AN/AN/A

Current Analyst Ratings

Latest GWPH, SRPT, WIZP, HCM, and LEGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/23/2024
Legend Biotech Co. stock logo
LEGN
Legend Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$87.00
4/17/2024
Legend Biotech Co. stock logo
LEGN
Legend Biotech
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSector Perform ➝ Sector Outperform$65.00
4/16/2024
Legend Biotech Co. stock logo
LEGN
Legend Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$87.00
4/3/2024
Legend Biotech Co. stock logo
LEGN
Legend Biotech
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$82.00
4/1/2024
Legend Biotech Co. stock logo
LEGN
Legend Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$87.00
3/18/2024
Legend Biotech Co. stock logo
LEGN
Legend Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$87.00
3/18/2024
Legend Biotech Co. stock logo
LEGN
Legend Biotech
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$76.00 ➝ $81.00
3/13/2024
Legend Biotech Co. stock logo
LEGN
Legend Biotech
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$86.00
3/7/2024
Legend Biotech Co. stock logo
LEGN
Legend Biotech
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$85.00
3/1/2024
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$164.00 ➝ $167.00
2/29/2024
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$128.00
(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
GW Pharmaceuticals plc stock logo
GWPH
GW Pharmaceuticals
$311.33M22.05$0.01 per share18,588.22$23.48 per share9.33
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
$838M3.79$0.69 per share26.38$4.27 per share4.27
Legend Biotech Co. stock logo
LEGN
Legend Biotech
$285.14M30.27N/AN/A$6.88 per share6.90
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$1.24B8.85N/AN/A$9.19 per share12.74
Mawson Infrastructure Group Inc. stock logo
WIZP
Mawson Infrastructure Group
N/AN/AN/AN/A$0.03 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
GW Pharmaceuticals plc stock logo
GWPH
GW Pharmaceuticals
-$9.02M-$0.24N/A608.22N/A-11.05%-7.46%-6.13%N/A
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
$100.78MN/A0.0038.02N/AN/AN/AN/A5/22/2024 (Estimated)
Legend Biotech Co. stock logo
LEGN
Legend Biotech
-$518.25M-$1.48N/A593.13N/A-181.75%-37.19%-25.34%5/13/2024 (Confirmed)
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
-$535.98M-$6.12N/A14.71N/A-43.11%-18.97%-4.65%5/7/2024 (Estimated)
Mawson Infrastructure Group Inc. stock logo
WIZP
Mawson Infrastructure Group
-$3.45M-$0.33N/AN/AN/AN/AN/A-85.32%N/A

Latest GWPH, SRPT, WIZP, HCM, and LEGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2024N/A
Legend Biotech Co. stock logo
LEGN
Legend Biotech
-$0.23N/A+$0.23N/AN/AN/A  
3/11/2024Q4 2023
Legend Biotech Co. stock logo
LEGN
Legend Biotech
-$0.70-$0.40+$0.30-$0.40$95.63 million$76.50 million    
2/28/2024Q4 23
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
-$0.03$0.47+$0.50$0.47$387.18 million$396.80 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
GW Pharmaceuticals plc stock logo
GWPH
GW Pharmaceuticals
N/AN/AN/AN/AN/A
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
N/AN/AN/AN/AN/A
Legend Biotech Co. stock logo
LEGN
Legend Biotech
N/AN/AN/AN/AN/A
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
N/AN/AN/AN/AN/A
Mawson Infrastructure Group Inc. stock logo
WIZP
Mawson Infrastructure Group
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
GW Pharmaceuticals plc stock logo
GWPH
GW Pharmaceuticals
0.01
5.13
4.31
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
0.06
2.72
2.60
Legend Biotech Co. stock logo
LEGN
Legend Biotech
0.22
6.92
6.83
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
1.32
3.95
3.45
Mawson Infrastructure Group Inc. stock logo
WIZP
Mawson Infrastructure Group
N/A
1.13
1.13

Ownership

Institutional Ownership

CompanyInstitutional Ownership
GW Pharmaceuticals plc stock logo
GWPH
GW Pharmaceuticals
81.00%
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
8.82%
Legend Biotech Co. stock logo
LEGN
Legend Biotech
70.89%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
86.68%
Mawson Infrastructure Group Inc. stock logo
WIZP
Mawson Infrastructure Group
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
GW Pharmaceuticals plc stock logo
GWPH
GW Pharmaceuticals
1,16131.35 millionN/AOptionable
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
1,988174.25 million167.98 millionNot Optionable
Legend Biotech Co. stock logo
LEGN
Legend Biotech
1,800181.91 million181.88 millionOptionable
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
1,31493.90 million86.95 millionOptionable
Mawson Infrastructure Group Inc. stock logo
WIZP
Mawson Infrastructure Group
2486.32 millionN/ANot Optionable

GWPH, SRPT, WIZP, HCM, and LEGN Headlines

SourceHeadline
Mawson Infrastructure Group adds new customer at Midland bitcoin facilityMawson Infrastructure Group adds new customer at Midland bitcoin facility
bizjournals.com - December 20 at 11:39 AM
Mawson announces agreement for half of Midland bitcoin facility capacityMawson announces agreement for half of Midland bitcoin facility capacity
bizjournals.com - October 19 at 5:32 PM
Mawson Infrastructure reports BTC production of 69 in July, down 3% M/MMawson Infrastructure reports BTC production of 69 in July, down 3% M/M
seekingalpha.com - August 24 at 6:28 PM
H.C. Wainwright Sticks to Its Buy Rating for Mawson Infrastructure Group (MIGI)H.C. Wainwright Sticks to Its Buy Rating for Mawson Infrastructure Group (MIGI)
markets.businessinsider.com - August 24 at 7:44 AM
Mawson Infrastructure Group Inc. Invites Submission of Indication of Interest for its BTC Hosting and HPC Co-location ServicesMawson Infrastructure Group Inc. Invites Submission of Indication of Interest for its BTC Hosting and HPC Co-location Services
technews.tmcnet.com - July 25 at 10:20 AM
Mawson Infrastructure Group Inc. Announces Monthly Operational Update for June 2023Mawson Infrastructure Group Inc. Announces Monthly Operational Update for June 2023
businesswire.com - July 19 at 10:01 AM
Mawson Infrastructure Group Inc. Announces Monthly Operational Update for May 2023Mawson Infrastructure Group Inc. Announces Monthly Operational Update for May 2023
technews.tmcnet.com - June 14 at 10:10 AM
Mawson Infrastructure Group names new president, CEOMawson Infrastructure Group names new president, CEO
bizjournals.com - May 22 at 12:56 PM
With Significant Increases In Megawatt Capacity And Bitcoin Production, Mawson Infrastructure Group (NASDAQ: MIGI) May Attract More Bitcoin Mining InvestorsWith Significant Increases In Megawatt Capacity And Bitcoin Production, Mawson Infrastructure Group (NASDAQ: MIGI) May Attract More Bitcoin Mining Investors
msn.com - April 11 at 10:13 AM
Earnings Outlook For Mawson InfrastructureEarnings Outlook For Mawson Infrastructure
msn.com - November 12 at 8:40 PM
Bitcoin Miner CleanSpark Buys Mawson Site as Consolidation RisesBitcoin Miner CleanSpark Buys Mawson Site as Consolidation Rises
finance.yahoo.com - September 11 at 12:26 AM
Mawson Infrastructure Group Inc. To Sell Sandersville, Georgia Bitcoin Mining Facility including 6468 ASIC Bitcoin Miners To CleanSpark, Inc. For Up To $42.5 MillionMawson Infrastructure Group Inc. To Sell Sandersville, Georgia Bitcoin Mining Facility including 6468 ASIC Bitcoin Miners To CleanSpark, Inc. For Up To $42.5 Million
benzinga.com - September 9 at 10:20 AM
Why Bitcoin- And Ethereum-Related Stock CleanSpark Is Rising TodayWhy Bitcoin- And Ethereum-Related Stock CleanSpark Is Rising Today
benzinga.com - September 9 at 10:20 AM
Mawson Infrastructure Group Inc. Announces July 2022 Bitcoin Self-Mining, Hosting Co-location, Energy Demand Response and Operational UpdateMawson Infrastructure Group Inc. Announces July 2022 Bitcoin Self-Mining, Hosting Co-location, Energy Demand Response and Operational Update
finance.yahoo.com - August 25 at 10:24 AM
Mawson Infrastructure Group Inc. Schedules Second Quarter Results Webcast for 5:30 p.m. ET on August 22, 2022Mawson Infrastructure Group Inc. Schedules Second Quarter Results Webcast for 5:30 p.m. ET on August 22, 2022
benzinga.com - August 18 at 9:55 AM
Bitcoin Miner Mawson Infrastructure Produced 185 Bitcoin In Record-Breaking MayBitcoin Miner Mawson Infrastructure Produced 185 Bitcoin In Record-Breaking May
bitcoinmagazine.com - June 16 at 3:23 PM
Mawson to Develop New Bitcoin Mining Site in TexasMawson to Develop New Bitcoin Mining Site in Texas
finance.yahoo.com - May 17 at 2:50 AM
Mawson Infrastructure Group Inc. Announces New 120 Megawatt Bitcoin Mining Facility in Texas, USAMawson Infrastructure Group Inc. Announces New 120 Megawatt Bitcoin Mining Facility in Texas, USA
tmcnet.com - May 16 at 9:34 AM
Texas Pacific Land Corporation, Mawson Infrastructure Group Inc., and JAI Energy Announce New Bitcoin Mining Venture in West TexasTexas Pacific Land Corporation, Mawson Infrastructure Group Inc., and JAI Energy Announce New Bitcoin Mining Venture in West Texas
tmcnet.com - May 16 at 9:34 AM
Mawson Infrastructure Group discusses Q3 highlights including Quinbrook renewable energy partnershipMawson Infrastructure Group discusses Q3 highlights including Quinbrook renewable energy partnership
proactiveinvestors.com - December 14 at 11:45 PM
Audacious Secures $20M Funding & Closes $3.1M Non-Brokered Private Placement TrancheAudacious Secures $20M Funding & Closes $3.1M Non-Brokered Private Placement Tranche
benzinga.com - December 11 at 11:01 PM
Essential Investment? This REIT Believes in Cannabis-Related Real EstateEssential Investment? This REIT Believes in Cannabis-Related Real Estate
benzinga.com - December 9 at 6:25 PM
South Dakotas Supreme Strikes Down Recreational Cannabis Vote, Overturning Peoples WillSouth Dakota's Supreme Strikes Down Recreational Cannabis Vote, Overturning People's Will
benzinga.com - November 28 at 6:55 PM
10 Weed Strains For People Who Like Cheese10 Weed Strains For People Who Like Cheese
benzinga.com - November 8 at 12:11 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

GW Pharmaceuticals logo

GW Pharmaceuticals

NASDAQ:GWPH
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas. Its lead product is Epidiolex, an oral medicine for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of schizophrenia, autism spectrum disorder, neuropsychiatric symptom, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.
HUTCHMED logo

HUTCHMED

NASDAQ:HCM
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
Legend Biotech logo

Legend Biotech

NASDAQ:LEGN
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
Sarepta Therapeutics logo

Sarepta Therapeutics

NASDAQ:SRPT
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Mawson Infrastructure Group logo

Mawson Infrastructure Group

OTCMKTS:WIZP
Mawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company is headquartered in North Sydney, Australia.